Literature DB >> 30237250

Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.

Babatunde O Akinwunmi1,2, Ana Babic3, Allison F Vitonis4, Daniel W Cramer4,5,6, Linda Titus7, Shelley S Tworoger5,8, Kathryn L Terry4,5,6.   

Abstract

BACKGROUND: Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer.
METHODS: We used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA125II assay and calculated the association between medical conditions and log-transformed CA125 using linear regression.
RESULTS: The median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/mL for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps (P = 0.06) and hysterectomy (P = 0.01) and significantly higher with endometriosis (P = 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) (P < 0.01, n = 2 cases) but not among postmenopausal with CVD (n = 79). Furthermore, among postmenopausal women, CA125 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis (P = 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease (P = 0.04).
CONCLUSIONS: Several chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening. IMPACT: Consideration of chronic medical conditions may be necessary to interpret CA125 values. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30237250      PMCID: PMC6279537          DOI: 10.1158/1055-9965.EPI-18-0203

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  48 in total

1.  Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women.

Authors:  Chung-Lieh Hung; Ta-Chuan Hung; Chun-Chun Liu; Yih-Jer Wu; Jen-Yuan Kuo; Charles Jia-Yin Hou; Hung-I Yeh
Journal:  Am J Cardiol       Date:  2012-06-22       Impact factor: 2.778

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  CA-125: a biomarker put to the test.

Authors:  Charlie Schmidt
Journal:  J Natl Cancer Inst       Date:  2011-08-17       Impact factor: 13.506

4.  Ovarian cancer screening and early detection in the general population.

Authors:  Jose A Rauh-Hain; Thomas C Krivak; Marcela G Del Carmen; Alexander B Olawaiye
Journal:  Rev Obstet Gynecol       Date:  2011

5.  Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy.

Authors:  Allison F Vitonis; Linda Titus-Ernstoff; Daniel W Cramer
Journal:  Obstet Gynecol       Date:  2011-05       Impact factor: 7.661

6.  Relationship between the serum CA-125 level and bone mineral density in healthy pre- and post-menopausal women.

Authors:  Ki Hoon Ahn; Hyun Tae Park; Tak Kim; Jun Young Hur; Young Tae Kim; Kyu Wan Lee; Sun Haeng Kim
Journal:  Aust N Z J Obstet Gynaecol       Date:  2010-08       Impact factor: 2.100

7.  Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer.

Authors:  Wa Zhong; Zhong Yu; Jun Zhan; Tao Yu; Ying Lin; Zhong-Sheng Xia; Yu-Hong Yuan; Qi-Kui Chen
Journal:  Pathol Oncol Res       Date:  2014-05-30       Impact factor: 3.201

8.  Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2017-01-03       Impact factor: 2.506

9.  Serum CA125 concentration has inverse correlation with metabolic syndrome.

Authors:  Nam-Seok Joo; Kyu-Nam Kim; Kyung Soo Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

Review 10.  CA 125: the past and the future.

Authors:  R C Bast; F J Xu; Y H Yu; S Barnhill; Z Zhang; G B Mills
Journal:  Int J Biol Markers       Date:  1998 Oct-Dec       Impact factor: 3.248

View more
  9 in total

1.  Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.

Authors:  Xiao Hu; Jingzhou Zhang; Yu Cao
Journal:  BMC Cancer       Date:  2022-05-14       Impact factor: 4.638

2.  The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy.

Authors:  Shoichiro Yamanaka; Naoki Kawahara; Ryuji Kawaguchi; Keita Waki; Tomoka Maehana; Yosuke Fukui; Ryuta Miyake; Yuki Yamada; Hiroshi Kobayashi; Fuminori Kimura
Journal:  Diagnostics (Basel)       Date:  2022-05-12

3.  Aging-related changes in the gene expression profile of human lungs.

Authors:  Ina Jeong; Jae-Hyun Lim; Jin-Soo Park; Yeon-Mok Oh
Journal:  Aging (Albany NY)       Date:  2020-11-09       Impact factor: 5.682

Review 4.  Endometriosis and ovarian cancer risk, an epigenetic connection.

Authors:  Sarah Brunty; Brenda Mitchell; Nadim Bou-Zgheib; Nalini Santanam
Journal:  Ann Transl Med       Date:  2020-12

Review 5.  CA125 and Ovarian Cancer: A Comprehensive Review.

Authors:  Parsa Charkhchi; Cezary Cybulski; Jacek Gronwald; Fabian Oliver Wong; Steven A Narod; Mohammad R Akbari
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

Review 6.  The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.

Authors:  Cailin O'Connell; Sabrina VandenHeuvel; Aparna Kamat; Shreya Raghavan; Biana Godin
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

7.  Serum CA125 Level Is Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes.

Authors:  Litong Yao; Yifan Zhong; Lingzi He; Yan Wang; Jingyang Wu; Jin Geng; Yun Zhou; Jiahua Zhang; Jun Chen; Zhongyan Shan; Weiping Teng; Yingying Xu; Lei Chen; Lei Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-22       Impact factor: 3.168

8.  Study on the Application of Systemic Inflammation Response Index and Platelet-Lymphocyte Ratio in Ovarian Malignant Tumors.

Authors:  Huifang Huang; Kunhai Wu; Lufei Chen; Xiaomei Lin
Journal:  Int J Gen Med       Date:  2021-12-18

9.  CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels.

Authors:  Yi-Sheng Wang; Shi-Fang Ren; Wei Jiang; Jia-Qi Lu; Xiao-Yan Zhang; Xiao-Ping Li; Rui Cao; Cong-Jian Xu
Journal:  Ann Transl Med       Date:  2021-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.